Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.97M rose 123.4% year over year, ahead of the +76.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 9.0% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.

Context

  • Stock-based compensation amounted to 45.9% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +123.4% holds above the trailing-twelve-month pace of +76.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.97M+9.0% QoQ
Last fiscal yearDec 2025
$6.02M+25.9% YoY
LTMMar 2026
$7M+76.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+123.4%——
1 year+25.9%——
3-year CAGR-18.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.02M USD
Year-over-year change
+25.9%
4-year CAGR
-6.6%

Stock-Based Compensation vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +76.4% is the 3rd highest of 10, against a peer median of +7.9%.
  • Stock-based compensation amounts to 39.9% of revenue for TNXP, versus a peer median of 344.3%.
TNXP Competitors
Stock-Based Compensation for TNXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M USD-43.3%-31.8%340.0%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$9.79M USD-31.5%+8.6%—
MCRBSeres Therapeutics, Inc.LTM Mar 2026$9.79M USD-43.4%-24.8%853.3%
FBRXForte Biosciences, Inc.LTM Mar 2026$7.82M USD+99.9%+15.9%—
NKTXNkarta, Inc.LTM Mar 2026$7.62M USD-49.8%-20.2%—
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$7M USD+76.4%-18.0%39.9%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$6.14M USD+9.4%-6.2%344.3%
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.05M USD+83.8%+67.0%—
Peer median (excluding TNXP) —+7.9%+0.1%344.3%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
Deferred Income Tax00000
Stock-Based Compensation7.9M10.91M9.28M4.78M6.02M
Change in Working Capital5.78M(2K)(35K)5.78M8.55M
Accounts Receivables000(3.68M)(2.62M)
Inventory0061K3.74M1.73M
Accounts Payables3.53M(1.05M)(3.49M)927K2.99M
Other Working Capital2.26M1.04M3.39M4.79M6.44M
Other Non-Cash Items3M10.91M1.12M55.14M7.69M
Operating Cash Flow(75.56M)(98.05M)(102M)(60.93M)(99.84M)
Capital Expenditures(35.31M)(48.15M)(7.9M)(120K)(3.37M)
Acquisitions (Net)00(22.17M)00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00999K0(1.16M)
Investing Cash Flow(35.31M)(48.15M)(29.07M)(120K)(4.53M)
Debt Repayment008.94M(2.35M)(9.65M)
Common Stock Issued212.39M94.46M18.94M140.2M237.94M
Common Stock Repurchased00(13.97M)0(13.76M)
Dividends Paid00000
Other Financing Activities98K40K22.6M(2.97M)0
Financing Cash Flow212.49M87.84M36.52M134.87M214.53M
Effect of Forex Changes(31K)(74K)(65K)4K(31K)
Net Change in Cash101.59M(58.43M)(94.62M)73.83M110.13M
Free Cash Flow(110.86M)(146.2M)(109.9M)(61.05M)(103.21M)

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.